Correction: The meaning of lymphadenopathies during adjuvant durvalumab after chemoradiotherapy for lung cancer: thinking beyond disease progression

Pantarotto, Marcos; Barata, Rita; Coelho, Ricardo; Sousa, Virginia; Carvalheiro, Catarina; Rolim, Ines; Garrido, Patricia; GIl, Nuno; Duarte-Ramos, Filipa; Tonin, Fernanda

http://hdl.handle.net/10400.21/15726

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Correction_The meaning of lymphadenopathies during adjuvant durvalumab after chemoradiotherapy for lung cancer_thinking beyond disease progression.pdf		46.38 KB	Adobe PDF	Download

Send Feedback

Authors

Carvalheiro, Catarina

Abstract(s)

This article has been corrected at the request of the authors to include Virginia Sousa as the fourth author as she was erroneously omitted during the submission process. The authors deeply regret that this error was not identified and addressed prior to publication.

Keywords

Immune-checkpoint inhibitors Pseudoprogression Immune-related adverse events Lung cancer Differential diagnosis

URI

http://hdl.handle.net/10400.21/15726

Citation

Pantarotto M, Barata R, Coelho R, Cavalheiro C, Rolim I, Tonin FS, et al. Correction: The meaning of lymphadenopathies during adjuvant durvalumab after chemoradiotherapy for lung cancer: thinking beyond disease progression. Cureus. 2023;15(2):c101.